Clearside Biomedical Inc (NAS:CLSD)
$ 1.15 0 (0%) Market Cap: 85.96 Mil Enterprise Value: 57.46 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 64/100

Clearside Biomedical Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 02:50PM GMT
Release Date Price: $1.18 (-2.48%)
Albert Lowe
Piper Sandler Finance, LLC - Analyst

Hi, everyone. My name is Albert Lowe. I'm from the Piper Sandler biotech team. And it's my pleasure to welcome the team from Clearside Biomedical, and here to present the latest update on their unique delivery system to deliver therapy to the back of the eye using the suprachoroidal space is the CSO (sic -- Chief Medical Officer), Tom Ciulla. So, I'll hand it over. Thank you.

Tom Ciulla
Clearside Biomedical, Inc. - Chief Medical Officer and Chief Development Officer

Thank you, Albert, and thank you to Piper Sandler for having us here today. I'd like to remind you that I'm going to make some forward-looking statements. Our risks as summarized on this slide, and of course, on our website where you can download our SEC filings.

Clearside is developing and delivering treatments that restore and preserve vision for serious back of the eye disorders. We have a versatile therapeutic platform with our SCS Microinjector with proprietary drug formulations that target suprachoroidal space. We have a two-pronged

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot